Today at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, Genialis, a leading RNA-biomarker company, unveiled their latest AI/ML classifier, Genialis™ krasID. This innovative tool…
Australian biotech firm, Ferronova, has commenced a clinical trial featuring their FerroTrace® nanoparticle technology in individuals diagnosed with gastric and esophageal cancers. This trial follows the successful completion of a…
Onchilles Pharma, a pioneering biotech firm specializing in cancer treatments harnessing a unique innate immune approach for targeted and potent tumor eradication, revealed groundbreaking preclinical findings today. The data pertained…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a prominent RNAi therapeutics firm, has unveiled encouraging outcomes from the KARDIA-2 Phase 2 trial. This study assessed the effectiveness and safety of a single…
Edgewood Oncology, a biotech company specializing in BTX-A51 treatments for hematologic malignancies and solid tumors, has revealed fresh preclinical findings. The study, conducted by Dana-Farber Cancer Institute and Hebrew University-Hadassah…
Natera, a leader in cell-free DNA testing, presents findings from the IMvigor011 study at the EAU Congress 2024. The analysis focuses on muscle-invasive bladder cancer (MIBC) patients who tested negative…
Nucleai, a leader in spatial AI biomarkers, will present pioneering advancements in cancer diagnostics at the AACR Annual Meeting. Their posters will introduce novel AI spatial biomarkers and enhanced histopathology…
Seek Labs, a healthcare innovations company focused on next-generation molecular diagnostic systems and CRISPR-based gene therapies, is excited to welcome Dr. Randy Rasmussen, PhD, to its Board of Directors. Dr.…
The report on “Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product with Price and Volume Outlook, including Executive and Consultant Guides, and Customized Forecasting and Analysis for 2023-2027”…
Castle Biosciences, Inc. (Nasdaq: CSTL), a company focused on improving patient care through innovative tests, has announced the presentation of new data showcasing the performance of its DecisionDx-Melanoma test in…
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. have made a joint announcement regarding the recent developments related to bempedoic acid (marketed as NILEMDO®) and the bempedoic acid/ezetimibe fixed combination…
Esperion (NASDAQ: ESPR) announced today that the FDA has approved expanded labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets. This approval is based on positive…